

To: [redacted] (10)(2e) [redacted] (10)(2e) @rivm.nl; [redacted] (10)(2e) [redacted] (10)(2e) @kemri-wellcome.org; [redacted] (10)(2e) [redacted] (10)(2e) @kemri-wellcome.org; [redacted] (10)(2e) [redacted] (10)(2e) @kemri-wellcome.org; [redacted] (10)(2e) [redacted] (10)(2e) @kemri-wellcome.org; [redacted] (10)(2e) [redacted] (10)(2e) @kemri-wellcome.org; [redacted] (10)(2e) [redacted] (10)(2e) @rivm.nl; [redacted] (10)(2e) [redacted] (10)(2e) @kemri-wellcome.org; [redacted] (10)(2e) [redacted] (10)(2e) @ikilifi.org
Cc: [redacted] (10)(2e) [redacted] (10)(2e) @kemri-wellcome.org; [redacted] (10)(2e) [redacted] (10)(2e) @ishtm.ac.uk; [redacted] (10)(2e) [redacted] (10)(2e) @kemri-wellcome.org
From: [redacted] (10)(2e)
Sent: Mon 8/17/2020 10:11:35 AM
Subject: RE: COvId19 and Measles serology manuscript
Received: Mon 8/17/2020 10:11:36 AM
[COVID19 and Measles SIA paper_ver1_12APR20_PvG_FK.docx](#)

Dear [redacted] (10)(2e)

Thank you for this very nice work and thank you for offering a co-authorship.
 It underlines the importance of getting vaccination coverage back to pre-covid as soon as possible.
 I have a few minor comments,

Regards,
 [redacted] (10)(2e)

From: [redacted] (10)(2e) <[redacted] (10)(2e) @rivm.nl>
Sent: vrijdag 14 augustus 2020 16:10
To: [redacted] (10)(2e) <[redacted] (10)(2e) @kemri-wellcome.org>; [redacted] (10)(2e) <[redacted] (10)(2e) @kemri-wellcome.org>; [redacted] (10)(2e) <[redacted] (10)(2e) @kemri-wellcome.org>; [redacted] (10)(2e) <[redacted] (10)(2e) @kemri-wellcome.org>; [redacted] (10)(2e) <[redacted] (10)(2e) @kemri-wellcome.org>; [redacted] (10)(2e) <[redacted] (10)(2e) @kemri-wellcome.org>; [redacted] (10)(2e) <[redacted] (10)(2e) @rivm.nl>; [redacted] (10)(2e) <[redacted] (10)(2e) @rivm.nl>; [redacted] (10)(2e) <[redacted] (10)(2e) @kemri-wellcome.org>; [redacted] (10)(2e) <[redacted] (10)(2e) @ikilifi.org>
Cc: [redacted] (10)(2e) <[redacted] (10)(2e) @kemri-wellcome.org>; [redacted] (10)(2e) <[redacted] (10)(2e) @ishtm.ac.uk>; [redacted] (10)(2e) <[redacted] (10)(2e) @kemri-wellcome.org>
Subject: RE: COvId19 and Measles serology manuscript

Dear [redacted] (10)(2e)

Thank you for sharing the draft manuscript with us and honor our contribution for the assay development/optimization/transfer with a co-authorship. I am happy to be included in the list of authors and agree with the order as currently proposed.
 I enjoyed reading this well written manuscript. It is a very interesting subject related to the present COVID19 situation and a very topical issue.

I have added some minor suggestions in the attached file 'COVID19 and Measles SIA paper_ver1_12APR20_PvG'.

Success with the submission to the Lancet Global Health.

Warm regards,
 [redacted] (10)(2e)

[redacted] (10)(2e), BAsc | Senior Research Technician | Centre for Immunology of Infectious Diseases and Vaccines |
 National Institute for Public Health and the Environment (RIVM) | Antonie van Leeuwenhoeklaan 9 |
 PO box 1 | 3720 BA BILTHOVEN | The Netherlands
 T: [redacted] (10)(2e) [redacted] (10)(2e) [redacted] (10)(2e) [redacted] (10)(2e) E: [redacted] (10)(2e) @rivm.nl

From: [redacted] (10)(2e) <[redacted] (10)(2e) @kemri-wellcome.org>
Sent: donderdag 13 augustus 2020 19:34
To: [redacted] (10)(2e) <[redacted] (10)(2e) @kemri-wellcome.org>; [redacted] (10)(2e) <[redacted] (10)(2e) @kemri-wellcome.org>; [redacted] (10)(2e) <[redacted] (10)(2e) @kemri-wellcome.org>; [redacted] (10)(2e) <[redacted] (10)(2e) @kemri-wellcome.org>; [redacted] (10)(2e) <[redacted] (10)(2e) @rivm.nl>; [redacted] (10)(2e) <[redacted] (10)(2e) @rivm.nl>; [redacted] (10)(2e) <[redacted] (10)(2e) @rivm.nl>; [redacted] (10)(2e) <[redacted] (10)(2e) @kemri-wellcome.org>; [redacted] (10)(2e) <[redacted] (10)(2e) @ikilifi.org>
Cc: [redacted] (10)(2e) <[redacted] (10)(2e) @kemri-wellcome.org>; [redacted] (10)(2e) <[redacted] (10)(2e) @ishtm.ac.uk>; [redacted] (10)(2e) <[redacted] (10)(2e) @kemri-wellcome.org>
Subject: COvId19 and Measles serology manuscript

Dear Colleagues,

I am happy to share this draft manuscript with you. It uses the results from our first set of measles serology data in a mathematical model to predict the likelihood of a measles outbreak given the COVID19 disruptions to routine immunization and campaigns. (10)(2e) my PhD student co-supervised with (10)(2e) and (10)(2e) has done the heavy lifting of running the models underpinning the results presented here whilst working closely with the modelling group at the LSHTM.

The author list includes all those who have contributed to this through data generation, assay development/optimization/transfer, fieldwork, etc. Please let me know if you are happy to be 1) included in the list of authors 2) are satisfied with order as currently proposed and 3) if there are others I have omitted inadvertently. Kindly review the acknowledgement section to confirm our funding sources have been included, etc.

The target journal is Lancet Global Health and we aim for submission on mid next week. So, we will appreciate your feedback latest Monday 17th August .

Thank you for your collaboration.

Warm regards

(10)(2e)

(10)(2e)

Clinical Epidemiologist

Epidemiology and Demography Department

KEMRI-Wellcome Trust Research Programme

CGMRC, PO Box 230-80108, Kilifi, Kenya

T +254 (10)(2e) (switchboard) +254 (10)(2e) (direct) | F +254 (10)(2e)

(10)(2e) [@kemri-wellcome.org](mailto:(10)(2e)@kemri-wellcome.org) | www.kemri-wellcome.org

This e-mail contains information which is confidential. It is intended only for the use of the named recipient. If you have received this e-mail in error, please let us know by replying to the sender, and immediately delete it from your system. Please note, that in these circumstances, the use, disclosure, distribution or copying of this information is strictly prohibited. KEMRI-Wellcome Trust Programme cannot accept any responsibility for the accuracy or completeness of this message as it has been transmitted over a public network. Although the Programme has taken reasonable precautions to ensure no viruses are present in emails, it cannot accept responsibility for any loss or damage arising from the use of the email or attachments. Any views expressed in this message are those of the individual sender, except where the sender specifically states them to be the views of KEMRI-Wellcome Trust Programme.
